Miranda Biven is a partner in the technology transactions practice and a member of the board of directors at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies based in the United States and abroad in complex partnering and licensing arrangements, mergers, acquisitions, divestitures, spin-outs, and other business arrangements. Miranda counsels clients on the legal and business issues associated with such transactions, as well as the full spectrum of technology and intellectual property-based agreements, including research and development agreements; manufacturing, supply, and distribution agreements; clinical trials arrangements; materials transfer agreements; and commercialization and co-commercialization agreements. She also regularly represents clients in their dealings with academic institutions and other not-for-profit organizations.
Miranda was named to San Diego Business Journal‘s 2023 “Leaders of Influence in the Life Sciences” special edition, which featured Miranda’s work advising IGM Biosciences in its landmark collaboration agreement with Sanofi in March 2022. Miranda was also recognized in the “Top Health Care Lawyers 2023” special report by the Daily Jounal. The accompanying profile highlights Miranda’s recent achievements including her role as lead counsel in the landmark collaboration agreement between IGM Biosciences and Sanofi. Miranda is also noted for her work with Denali Therapeutics in the company’s various high-value collaboration agreements and with Aristea Pharmaceuticals in strategic collaboration and option-to-acquire arrangement.
Prior to joining Wilson Sonsini in 2005, Miranda practiced in New York and Sydney, Australia.